Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03350035 · ClinicalTrials.gov registry record · Phase 2
Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus
A Phase 2 study, sponsored by Marinus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT03350035 is a Phase 2 study that has completed, run by Marinus Pharmaceuticals. The registered enrollment target is 17 participants.
The verdict
NCT03350035, a Phase 2 study, has completed, sponsored by Marinus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
This study will evaluate the effectiveness and safety of an investigational drug, IV ganaxolone, as adjunctive therapy to standard of care to treat subjects with status epilepticus.
Interventions
- DRUG IV Ganaxolone active
- DRUG IV Placebo, non-active
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2018-02-19 |
| Est. Completion | 2019-09-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03350035
The ClinicalTrials.gov registry entry for NCT03350035 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Marinus Pharmaceuticals, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which IV Ganaxolone active is the first listed.
NCT03350035 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03350035 about?
NCT03350035 is a clinical study titled "Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus". This study will evaluate the effectiveness and safety of an investigational drug, IV ganaxolone, as adjunctive therapy to standard of care to treat subjects with status epilepticus.
What is the current status of trial NCT03350035?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2018-02-19. Estimated completion is 2019-09-18.
What interventions are being tested in trial NCT03350035?
The interventions under investigation include: IV Ganaxolone active (DRUG), IV Placebo, non-active (DRUG).
Who is sponsoring clinical trial NCT03350035?
This trial is sponsored by Marinus Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.